The Design and Development of Novel Drugs and Vaccines

Tarun Kumar Bhatt is an Assistant Professor in the Department of Biotechnology, at the Central University of Rajasthan, India. He received his PhD from the International Centre for Genetic Engineering and Biotechnology, New Delhi and gained post-doctoral experience at the Scripps Research Institute in San Diego, California. He has published over 25 articles and has extensive experience researching drug and vaccine development. Surendra Nimesh, UGC Assistant Professor at Central University of Rajasthan, Rajasthan, India. Surendra received his M.S. in Biomedical Science from the Dr. B.R. Ambedkar Center for Biomedical Research (ACBR), University of Delhi. He completed his PhD. In Nanotechnology at the Institute of Genomics and Integrative Biology (CSIR), Delhi. After completing his postdoctoral studies at the Ecole Polyetchnique of Montreal, Surendra joined the Clinical Research Institute of Montreal (IRCM), Canada as Postdoctoral Fellow. After completing his commitment at IRCM, he joined McGill University for short time. He also worked as NSERC visiting fellow at Health Canada, Canada. His research interests include nanoparticles-mediated gene, siRNA and drug delivery.

1. Introduction of structural bioinformatics with respect to drug discovery 2. Target identification and validation 3. Retrieval of compounds 4. Lead identification and optimization 5. Molecular dynamics simulations 6. An overview of vaccine design 7. Key steps in the selection of vaccine targets 8. Epitope prediction and selection of linkers and adjuvant 9. Design of vaccine constructs 10. In-silico validation through protein-protein docking 11. Molecular cloning 12. Protein expression 13. Protein purification and desalting 14. Biological assay 15. Biophysical methods 16. Outline of animal study for lead/ vaccine testing 17. Evaluation of immunogenicity of vaccine candidate 18. In-vitro evaluation of lead molecule 19. Medical physiological parameter for lead/vaccine testing 20. Brief introduction of clinical research and trials 21. An overview of IND, NDA, approval agencies and FDA post-marketing surveillance 22. Introduction of Intellectual property rights